Cyclerion Therapeutics (NASDAQ:CYCN – Get Rating) and Immutep (NASDAQ:IMMP – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, analyst recommendations, profitability, institutional ownership and earnings.
Valuation & Earnings
This table compares Cyclerion Therapeutics and Immutep's top-line revenue, earnings per share (EPS) and valuation.
Get Cyclerion Therapeutics alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cyclerion Therapeutics | $479,000.00 | 62.02 | -$51.65 million | ($1.09) | -0.63 |
| Immutep | $4.90 million | 35.26 | -$23.37 million | N/A | N/A |
Immutep has higher revenue and earnings than Cyclerion Therapeutics.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Cyclerion Therapeutics and Immutep, as reported by MarketBeat.| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cyclerion Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Immutep | 0 | 0 | 0 | 0 | N/A |
Volatility and Risk
Cyclerion Therapeutics has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500. Comparatively, Immutep has a beta of 2.33, suggesting that its share price is 133% more volatile than the S&P 500.
Profitability
This table compares Cyclerion Therapeutics and Immutep's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cyclerion Therapeutics | -2,551.69% | -149.84% | -114.70% |
| Immutep | N/A | N/A | N/A |
Institutional & Insider Ownership
58.5% of Cyclerion Therapeutics shares are held by institutional investors. Comparatively, 6.1% of Immutep shares are held by institutional investors. 13.2% of Cyclerion Therapeutics shares are held by company insiders. Comparatively, 3.1% of Immutep shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Immutep beats Cyclerion Therapeutics on 6 of the 9 factors compared between the two stocks.
About Cyclerion Therapeutics
(Get Rating)
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP). The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
About Immutep
(Get Rating)
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK'781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.